Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
FLGT Stock Forecast 2025-2026
$20.06
Current Price
$610.70M
Market Cap
Buy 1
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to FLGT Price Targets
+24.6%
To High Target of $25.00
+14.7%
To Median Target of $23.00
-0.3%
To Low Target of $20.00
FLGT Price Momentum
+0.8%
1 Week Change
-6.4%
1 Month Change
-0.6%
1 Year Change
+8.6%
Year-to-Date Change
-20.1%
From 52W High of $25.11
+37.7%
From 52W Low of $14.57
📊 TOP ANALYST CALLS
Did FLGT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Fulgent Genetics is one of their latest high-conviction picks.
Latest FLGT Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, FLGT has a neutral consensus with a median price target of $23.00 (ranging from $20.00 to $25.00). Currently trading at $20.06, the median forecast implies a 14.7% upside. This outlook is supported by 1 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andrew Cooper at Raymond James, projecting a 24.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FLGT Analyst Ratings
1
Buy
2
Hold
0
Sell
FLGT Price Target Range
Low
$20.00
Average
$23.00
High
$25.00
Current: $20.06
Latest FLGT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FLGT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 6, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $23.00 |
| May 5, 2025 | Raymond James | Andrew Cooper | Outperform | Reiterates | $25.00 |
| Mar 4, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $16.00 |
| Nov 11, 2024 | Piper Sandler | David Westenberg | Neutral | Maintains | $22.00 |
| Mar 6, 2024 | Piper Sandler | David Westenberg | Neutral | Maintains | $25.00 |
| Dec 7, 2023 | UBS | Dan Leonard | Neutral | Initiates | $35.00 |
| Oct 16, 2023 | Piper Sandler | David Westenberg | Neutral | Maintains | $28.00 |
| Mar 2, 2023 | Credit Suisse | Dan Leonard | Outperform | Maintains | $45.00 |
| Dec 8, 2022 | Piper Sandler | David Westenberg | Neutral | Downgrade | $40.00 |
| Nov 18, 2022 | Raymond James | Andrew Cooper | Outperform | Initiates | $45.00 |
| Nov 14, 2022 | Credit Suisse | Dan Leonard | Outperform | Maintains | $50.00 |
| Nov 14, 2022 | Piper Sandler | David Westenberg | Overweight | Maintains | $65.00 |
| Aug 25, 2022 | Credit Suisse | Dan Leonard | Outperform | Initiates | $65.00 |
| May 16, 2022 | Piper Sandler | David Westenberg | Overweight | Maintains | $70.00 |
| Jan 25, 2022 | Oppenheimer | Kevin DeGeeter | Outperform | Maintains | $125.00 |
| Aug 10, 2021 | Credit Suisse | Katie Tryhane | Underperform | Maintains | $65.00 |
| Mar 5, 2021 | Piper Sandler | Steven Mah | Overweight | Maintains | $140.00 |
| Feb 1, 2021 | Oppenheimer | Kevin DeGeeter | Outperform | Maintains | $130.00 |
| Jan 8, 2021 | Credit Suisse | Underperform | Downgrade | $0.00 | |
| Nov 24, 2020 | BTIG | Neutral | Downgrade | $0.00 |
Fulgent Genetics Inc. (FLGT) Competitors
The following stocks are similar to Fulgent Genetics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
FLGT
Fulgent Genetics
mkt cap
610.70M
Fulgent Genetics Inc. (FLGT) Financial Data
Fulgent Genetics Inc. has a market capitalization of $610.70M with a P/E ratio of 0.0x. The company generates $292.45M in trailing twelve-month revenue with a -13.9% profit margin.
Revenue growth is +13.9% quarter-over-quarter, while maintaining an operating margin of -26.9% and return on equity of -3.7%.
Valuation Metrics
Market Cap
$610.70M
Enterprise Value
$288.77M
P/E Ratio
0.0x
PEG Ratio
-39.3x
Price/Sales
2.1x
Growth & Margins
Revenue Growth (YoY)
+13.9%
Gross Margin
+38.6%
Operating Margin
-26.9%
Net Margin
-13.9%
EPS Growth
+13.9%
Financial Health
Cash/Price Ratio
+52.5%
Current Ratio
6.3x
Debt/Equity
0.7x
ROE
-3.7%
ROA
-3.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Fulgent Genetics Inc. (FLGT) Business Model
About Fulgent Genetics Inc.
What They Do
Provides genetic testing and diagnostic solutions.
Business Model
The company operates a business model centered on next-generation sequencing (NGS) and genetic testing services. It generates revenue by offering a wide range of diagnostic solutions that assist healthcare providers and patients in understanding genetic conditions, including panels for oncology, reproductive health, and rare diseases.
Additional Information
Fulgent Genetics is a key player in precision medicine, contributing to the growing demand for personalized healthcare solutions. Its commitment to innovation is showcased through the continuous development of new testing solutions and an expanding testing catalog, which enhances patient care and treatment outcomes.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
1,313
CEO
Mr. Ming Hsieh
Country
United States
IPO Year
2016
Website
www.fulgentgenetics.comFulgent Genetics Inc. (FLGT) Latest News & Analysis
Latest News
Quick Summary
Pomerantz LLP is investigating claims for Fulgent Genetics, Inc. (NASDAQ: FLGT) investors. Interested parties can contact Danielle Peyton for more information.
Why It Matters
Investigation into Fulgent Genetics could indicate potential legal issues or financial concerns, impacting stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims for investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). Interested parties can contact Danielle Peyton for more information.
Why It Matters
Fulgent Genetics faces potential legal scrutiny, which could impact its stock price and investor confidence. Ongoing investigations may lead to financial repercussions for the company.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Fulgent Genetics, Inc. (NASDAQ:FLGT) investors. Interested parties can find more information at bgandg.com/FLGT.
Why It Matters
The investigation into Fulgent Genetics may indicate potential legal issues or financial irregularities, raising concerns about the company's stability and affecting its stock value.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). Affected investors can seek more information on the firm's website.
Why It Matters
The investigation into Fulgent Genetics could indicate potential legal issues or financial instability, prompting concern over the stock's performance and future valuation.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Fulgent Genetics, Inc. (NASDAQ:FLGT) investors. Interested parties can visit bgandg.com/FLGT for more information.
Why It Matters
Potential legal claims against Fulgent Genetics may indicate financial instability or misconduct, impacting stock value and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Pomerantz LLP is investigating claims for investors of Fulgent Genetics, Inc. (NASDAQ: FLGT). Interested parties should contact Danielle Peyton at the provided email or phone number.
Why It Matters
Pomerantz LLP's investigation into Fulgent Genetics may indicate potential legal issues or financial misconduct, affecting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About FLGT Stock
What is Fulgent Genetics Inc.'s (FLGT) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Fulgent Genetics Inc. (FLGT) has a median price target of $23.00. The highest price target is $25.00 and the lowest is $20.00.
Is FLGT stock a good investment in 2026?
According to current analyst ratings, FLGT has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.06. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FLGT stock?
Wall Street analysts predict FLGT stock could reach $23.00 in the next 12 months. This represents a 14.7% increase from the current price of $20.06. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fulgent Genetics Inc.'s business model?
The company operates a business model centered on next-generation sequencing (NGS) and genetic testing services. It generates revenue by offering a wide range of diagnostic solutions that assist healthcare providers and patients in understanding genetic conditions, including panels for oncology, reproductive health, and rare diseases.
What is the highest forecasted price for FLGT Fulgent Genetics Inc.?
The highest price target for FLGT is $25.00 from Andrew Cooper at Raymond James, which represents a 24.6% increase from the current price of $20.06.
What is the lowest forecasted price for FLGT Fulgent Genetics Inc.?
The lowest price target for FLGT is $20.00 from at , which represents a -0.3% decrease from the current price of $20.06.
What is the overall FLGT consensus from analysts for Fulgent Genetics Inc.?
The overall analyst consensus for FLGT is neutral. Out of 8 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $23.00.
How accurate are FLGT stock price projections?
Stock price projections, including those for Fulgent Genetics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 7, 2025 4:00 PM UTC